MAY 2, 2023
Biophytis strengthens its management team Appointment of Chiara Baccelli as Director of Pharmaceutical Operations and Quality Assurance Appointment of Nicolas Fellmann as Chief Financial Officer Fullscreen Mode
APRIL 28, 2023
Biophytis announces receipt of Nasdaq Notice Biophytis announced that it has received written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) dated April 24, 2023, indicating that, based on the reported stockholders’ equity of (€1,911,000) of Biophytis as reported in its 20-F, the Company does not meet the minimum shareholders’ equity criteria…
APRIL 19, 2023
Biophytis regains compliance with NASDAQ minimum bid price requirement Biophytis announced that it has received written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“NASDAQ”) dated April 14, 2022, indicating that Biophytis has regained compliance with the Nasdaq Global Select Market minimum bid price requirement. On October 20, 2022, the Nasdaq had notified…
APRIL 18, 2023
Biophytis Announces 2022 Financial Results and 2023 Perspectives €11.1M of available cash and equivalents on December 31, 2022, and financing instruments for a total of €22M allowing financial visibility beyond mid 2024 Positive results of the Phase 2-3 COVA study for the treatment of severe COVID-19 with Sarconeos (BIO101) Early Access Program (EAP) submission in…
MARCH 31, 2023
The Combined General Meeting will be held on second call on April 17, 2023 Fullscreen Mode
MARCH 27, 2023
Biophytis presented Sarconeos (BIO101) as a possible treatment candidate for long COVID after hospitalization during the 13th annual International Conference on Frailty and Sarcopenia Research (ICFSR) Fullscreen Mode
MARCH 20, 2023
Biophytis to Present Sarconeos’ (BIO101) Development as a Drug Candidate in Rare Neuromuscular Diseases at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference Fullscreen Mode
MARCH 17, 2023
Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program Fullscreen Mode
MARCH 09, 2023
Positive results from the Phase 2-3 COVA study presented at the 21st ERS 2023 Lung Science Conference .Biophytis announced that it presents the positive results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 at the European Respiratory Society 2023 21st Lung Science Conference taking place in Estoril, Portugal, between the 9th…
MARCH 02, 2023
Biophytis announces the signature of a master service agreement with Intsel Chimos, a pharmaceutical company that will operate Sarconeos (BIO101) in France for the treatment of severe forms of COVID-19 Biophytis and Intsel Chimos signed a master service agreement under which Intsel Chimos will be the operating pharmaceutical company/exploitant, partner and distributor in France for…